IMPAX Laboratories, Inc. Prevails In ALZA Corporations Appeal Related To Generic Version Of Ditropan(R) XL

Published: Sep 07, 2006

HAYWARD, Calif.--(BUSINESS WIRE)--Sept. 7, 2006--IMPAX Laboratories, Inc. (OTC:IPXL) announced that the U.S. Court of Appeals for the Federal Circuit upheld a lower court ruling in favor of IMPAX in its defense of a lawsuit brought by Alza Corporation, a Johnson & Johnson (NYSE:JNJ) unit. The suit alleged patent infringement related to IMPAX's filing of an Abbreviated New Drug Application (ANDA) for a generic version of Ditropan(R) XL (Oxybutynin Chloride) tablets, 5, 10 and 15 mg. Alza Pharmaceuticals markets Ditropan XL for the treatment of urge urinary incontinence. U.S. sales of Ditropan XL were approximately $350 million in the 12 months ended May 31, 2006, according to Wolters Kluwer Health.

Back to news